Protection against bacteremic pneumococcal infection by antibody to pneumolysin

Area of Science:

• Immunology
• Microbiology
• Infectious Diseases

Background:

• Pneumolysin is a key virulence factor produced by Streptococcus pneumoniae.
• Streptococcus pneumoniae causes significant morbidity and mortality worldwide.
• The protective role of human antibodies against pneumolysin requires further investigation.

Purpose of the Study:

• To test the hypothesis that human antibodies to pneumolysin confer protection against Streptococcus pneumoniae infection.
• To investigate the relationship between serum anti-pneumolysin IgG levels and the severity of pneumococcal pneumonia.
• To evaluate the efficacy of passive immunization with anti-pneumolysin IgG in a murine model.

Main Methods:

• Measurement of serum anti-pneumolysin IgG levels in patients with pneumococcal pneumonia (bacteremic and nonbacteremic) and healthy controls.
• Longitudinal analysis of IgG levels during convalescence in patients with bacteremic pneumonia.
• Administration of purified human anti-pneumolysin IgG to mice followed by challenge with Streptococcus pneumoniae.

Main Results:

• Patients with nonbacteremic pneumococcal pneumonia exhibited higher serum anti-pneumolysin IgG levels at hospital admission compared to bacteremic patients and controls.
• IgG levels increased significantly during convalescence in bacteremic pneumonia patients, reaching levels similar to nonbacteremic patients.
• Passive transfer of anti-pneumolysin IgG conferred dose-dependent protection in mice against lethal challenge with Streptococcus pneumoniae, evidenced by increased survival and negative blood cultures.

Conclusions:

• Human antibody to pneumolysin is associated with protection against severe pneumococcal pneumonia.
• Early neutralization of pneumolysin's effects in the alveoli by IgG may prevent bacteremia.
• Anti-pneumolysin IgG shows potential as a therapeutic or prophylactic agent against pneumococcal infections.